Effect of lamivudine treatment on plasma levels of transforming growth factor β1, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B

Table 2 Correlation expressed by r-value and its significance between analyzed biochemical indices and TGF-β₁, TIMP-1 or MMP-1 in chronic hepatitis B patients treated with lamivudine

	mean ± SE	TGF-β1	TIMP-1	MMP-1
Bil (mg%)	1.02 ± 0.06	0.049	0.119	-0.059
ALT (U/L)	74.50 ± 5.9	0.201a	0.247a	0.005
AST (U/L)	60.10 ± 5.2	0.244a	0.269a	-0.029
ALP (U/L)	96.10 ± 3.8	0.114	0.295a	-0.071
GGT (U/L)	47.70 ± 4.9	0.062	0.247a	-0.102
PI (%)	87.30 ± 1.5	-0.109	0.006	-0.065

Bil: bilirubin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; GGT: gamma glutamyltranspeptidase; PI: prothrombin index.

^aP < 0.05 vs other groups.